LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Regulatory considerations for biosimilars.

    Nellore, Ranjani

    Perspectives in clinical research

    2011  Volume 1, Issue 1, Page(s) 11–14

    Abstract: Currently there is considerable interest in the legislative debate around generic biological drugs or "biosimilars" in the EU and US due to the large, lucrative market that it offers to the industry. While some countries have issued a few regulatory ... ...

    Abstract Currently there is considerable interest in the legislative debate around generic biological drugs or "biosimilars" in the EU and US due to the large, lucrative market that it offers to the industry. While some countries have issued a few regulatory guidelines as well as product specific requirements, there is no general consensus as to a single, simple mechanism similar to the bioequivalence determination that leads to approval of generic small molecules all over the world. The inherent complex nature of the molecules, along with complicated manufacturing and analytical techniques to characterize them make it difficult to rely on a single human pharmacokinetic study for assurance of safety and efficacy. In general, the concept of comparability has been used for evaluation of the currently approved "similar" biological where a step by step assessment on the quality, preclinical and clinical aspects is made. In India, the focus is primarily on the availability and affordability of life-saving drugs. In this context every product needs to be evaluated on its own merit irrespective of the innovator brand. The formation of the National Biotechnology Regulatory Authority may provide a step in the right direction for regulation of these complex molecules. However, in order to have an efficient machinery for initial approval and ongoing oversight with a country-specific focus, cooperation with international authorities for granting approvals and continuous risk-benefit review is essential. Several steps are still needed for India to be perceived as a country that leads the world in providing quality biological products.
    Language English
    Publishing date 2011-06-30
    Publishing country India
    Document type Journal Article
    ZDB-ID 2593231-7
    ISSN 2229-5488 ; 2229-3485
    ISSN (online) 2229-5488
    ISSN 2229-3485
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Regulatory considerations for biosimilars

    Ranjani Nellore

    Perspectives in Clinical Research, Vol 1, Iss 1, Pp 11-

    2010  Volume 14

    Abstract: Currently there is considerable interest in the legislative debate around generic biological drugs or "biosimilars" in the EU and US due to the large, lucrative market that it offers to the industry. While some countries have issued a few regulatory ... ...

    Abstract Currently there is considerable interest in the legislative debate around generic biological drugs or "biosimilars" in the EU and US due to the large, lucrative market that it offers to the industry. While some countries have issued a few regulatory guidelines as well as product specific requirements, there is no general consensus as to a single, simple mechanism similar to the bioequivalence determination that leads to approval of generic small molecules all over the world. The inherent complex nature of the molecules, along with complicated manufacturing and analytical techniques to characterize them make it difficult to rely on a single human pharmacokinetic study for assurance of safety and efficacy. In general, the concept of comparability has been used for evaluation of the currently approved "similar" biological where a step by step assessment on the quality, preclinical and clinical aspects is made. In India, the focus is primarily on the availability and affordability of life-saving drugs. In this context every product needs to be evaluated on its own merit irrespective of the innovator brand. The formation of the National Biotechnology Regulatory Authority may provide a step in the right direction for regulation of these complex molecules. However, in order to have an efficient machinery for initial approval and ongoing oversight with a country-specific focus, cooperation with international authorities for granting approvals and continuous risk-benefit review is essential. Several steps are still needed for India to be perceived as a country that leads the world in providing quality biological products.
    Keywords Biologics ; Regulations ; Guidelines ; Equivalence ; Comparability ; Biosimilar ; Medicine ; R ; Medicine (General) ; R5-920
    Subject code 320
    Language English
    Publishing date 2010-01-01T00:00:00Z
    Publisher Wolters Kluwer Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.

    Prativadibhayankaram, Venkateshan S / Lee, Lawrence Soon-U / Lye, David / Xiaoying, Xu / Nellore, Ranjani / Pendharkar, Vishal / Hentze, Hannes / Guan, Siyu / Ayers, Benjamin J / Seah, Shirley G K / Chye, De Hoe / Talib, Najwa S N / Kaliaperumal, Nivashini / Ong, Wei Yee / Wong, Zi Xin / Au, Veonice B / Alok, Anshula / Connolly, John E / Boyd-Kirkup, Jerome D /
    Ingram, Piers J / Hanson, Brendon J / Ethirajulu, Kantharaj / O'Connell, Damian / Chan, Conrad E Z

    Infectious diseases and therapy

    2022  Volume 11, Issue 5, Page(s) 1999–2015

    Abstract: Introduction: AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-in-human study assessed safety, ...

    Abstract Introduction: AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-in-human study assessed safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AOD01 in healthy volunteers.
    Methods: Intravenous doses of AOD01 were evaluated in escalating cohorts [four single-dose cohorts (2, 5, 10, and 20 mg/kg) and one two-dose cohort (two doses of 20 mg/kg, 24 h apart)].
    Results: Twenty-three subjects were randomized to receive AOD01 or a placebo in blinded fashion. A total of 34 treatment-emergent adverse events (TEAEs) were reported; all were mild in severity. Related events (headache and diarrhea) were reported in one subject each. No event of infusion reactions, serious adverse event (SAE), or discontinuation due to AE were reported. The changes in laboratory parameters, vital signs, and electrocardiograms were minimal. Dose-related exposure was seen from doses 2 to 20 mg/kg as confirmed by C
    Conclusions: AOD01 was safe and well tolerated, demonstrated dose-related PK, non-immunogenic status, and sustained ex vivo neutralization of SARS-CoV-2 after single intravenous dose ranging from 2 to 20 mg/kg and two doses of 20 mg/kg and show good potential for treatment of SARS-CoV-2 infection. (Health Sciences Authority identifier number CTA2000119).
    Language English
    Publishing date 2022-09-04
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2701611-0
    ISSN 2193-6382 ; 2193-8229
    ISSN (online) 2193-6382
    ISSN 2193-8229
    DOI 10.1007/s40121-022-00681-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

    Vincenzo Teneggi / Veronica Novotny‐Diermayr / Lay Hoon Lee / Maryam Yasin / Pauline Yeo / Kantharaj Ethirajulu / Sylvia Bong Hwa Gan / Stephanie E. Blanchard / Ranjani Nellore / Dhananjay N. Umrani / Roberto Gomeni / Darren Lim Wan Teck / Greg Li / Qing Shu Lu / Yang Cao / Alex Matter

    Clinical and Translational Science, Vol 13, Iss 1, Pp 57-

    2020  Volume 66

    Abstract: In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have ... ...

    Abstract In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope and complexity of early clinical studies and first‐in‐human (FIH) studies in particular. However, limited work has been done to explore the impact of these two modalities, alone or in combination, on the scientific value and on the implementation of such articulated studies. We conducted an FIH study in HVs with an oncology targeted drug, an Mnk 1/2 small molecule inhibitor. In this article, we describe results, advantages, and limitations of an integrated clinical protocol with an oncology drug. We further discuss and indicate points to consider when designing and conducting similar scientifically and operationally demanding FIH studies.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Public aspects of medicine ; RA1-1270
    Subject code 610
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Wiley
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug.

    Teneggi, Vincenzo / Novotny-Diermayr, Veronica / Lee, Lay Hoon / Yasin, Maryam / Yeo, Pauline / Ethirajulu, Kantharaj / Gan, Sylvia Bong Hwa / Blanchard, Stephanie E / Nellore, Ranjani / Umrani, Dhananjay N / Gomeni, Roberto / Teck, Darren Lim Wan / Li, Greg / Lu, Qing Shu / Cao, Yang / Matter, Alex

    Clinical and translational science

    2019  Volume 13, Issue 1, Page(s) 57–66

    Abstract: In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have ... ...

    Abstract In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope and complexity of early clinical studies and first-in-human (FIH) studies in particular. However, limited work has been done to explore the impact of these two modalities, alone or in combination, on the scientific value and on the implementation of such articulated studies. We conducted an FIH study in HVs with an oncology targeted drug, an Mnk 1/2 small molecule inhibitor. In this article, we describe results, advantages, and limitations of an integrated clinical protocol with an oncology drug. We further discuss and indicate points to consider when designing and conducting similar scientifically and operationally demanding FIH studies.
    MeSH term(s) Administration, Oral ; Adult ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/diagnosis ; Clinical Protocols ; Electrocardiography ; Healthy Volunteers ; Hematologic Neoplasms/drug therapy ; Humans ; Intracellular Signaling Peptides and Proteins/antagonists & inhibitors ; Male ; Medical Oncology/methods ; Middle Aged ; Monitoring, Ambulatory/methods ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein-Serine-Threonine Kinases/antagonists & inhibitors ; Research Design ; Young Adult
    Chemical Substances Antineoplastic Agents ; Intracellular Signaling Peptides and Proteins ; Protein Kinase Inhibitors ; MKNK1 protein, human (EC 2.7.1.-) ; MKNK2 protein, human (EC 2.7.11.1) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2019-09-09
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2433157-0
    ISSN 1752-8062 ; 1752-8054
    ISSN (online) 1752-8062
    ISSN 1752-8054
    DOI 10.1111/cts.12678
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection.

    Chawla, Sonia / Ghosh, Soma / Sihorkar, Vaibhav / Nellore, Ranjani / Kumar, T R Shantha / Srinivas, Nuggehally R

    Biomedical chromatography : BMC

    2006  Volume 20, Issue 4, Page(s) 349–357

    Abstract: A simple, precise, accurate and rugged reversed-phase high-performance liquid chromatography (HPLC) method has been developed and validated for the simultaneous determination of five permeability model compounds, viz. antipyrine, metoprolol, ketoprofen, ... ...

    Abstract A simple, precise, accurate and rugged reversed-phase high-performance liquid chromatography (HPLC) method has been developed and validated for the simultaneous determination of five permeability model compounds, viz. antipyrine, metoprolol, ketoprofen, furosemide and phenol red. The method was intended to standardize rat in situ single-pass intestinal perfusion studies to assess the intestinal permeability of drugs in the market as well as new chemical entities. Optimum resolution was achieved by gradient elution on a Symmetry Shield C-18 analytical column with the mobile phase consisting of a mixture of aqueous potassium dihydrogen orthophosphate (pH 5.5; 0.01 m) and methanol at a flow rate of 1.5 mL/min. The retention times of antipyrine, metoprolol, ketoprofen, phenol red and furosemide were about 9, 12, 13, 16 and 17 min, respectively. Data acquisition was carried out using a photo diode array detector in the wavelength range 210-600 nm. Extraction of chromatograms was carried out by timed wavelength. Data obtained in all studies indicated that the method was suitable for the intended purpose. The validated method was found to be linear and precise in the working range. Suitability of storage under various conditions and freeze/thaw impact at cold temperature were established to ensure complete sample recovery without any stability issues. Recovery very close to the spiked amounts indicated that the method was highly accurate and suitable for use on routine basis.
    MeSH term(s) Animals ; Antipyrine/analysis ; Chromatography, High Pressure Liquid/instrumentation ; Chromatography, High Pressure Liquid/methods ; Drug Stability ; Furosemide/analysis ; Intestinal Absorption/physiology ; Ketoprofen/analysis ; Metoprolol/analysis ; Permeability ; Phenolsulfonphthalein/analysis ; Rats ; Reproducibility of Results ; Sensitivity and Specificity
    Chemical Substances Furosemide (7LXU5N7ZO5) ; Ketoprofen (90Y4QC304K) ; Metoprolol (GEB06NHM23) ; Phenolsulfonphthalein (I6G9Y0J1OJ) ; Antipyrine (T3CHA1B51H)
    Language English
    Publishing date 2006-04
    Publishing country England
    Document type Journal Article ; Validation Studies
    ZDB-ID 632848-9
    ISSN 1099-0801 ; 0269-3879
    ISSN (online) 1099-0801
    ISSN 0269-3879
    DOI 10.1002/bmc.570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Pre-clinical and clinical evaluation of solution and soft gelatin capsule formulations for a BCS class 3 compound with atypical physicochemical properties.

    Ramsay-Olocco, Karen / Alexandrova, Ludmila / Nellore, Ranjani / Killion, Robert / Li, Li / Coen, Patricia / Ho, Quynh / Jung, Donald / Rocha, Cynthia

    Journal of pharmaceutical sciences

    2004  Volume 93, Issue 9, Page(s) 2214–2221

    Abstract: R1481 is a sub-type selective muscarinic receptor antagonist with the potential treatment of overactive bladder. R1481 presents two challenges for drug development. The first is the viscous semi-solid nature of the active pharmaceutical ingredient (API). ...

    Abstract R1481 is a sub-type selective muscarinic receptor antagonist with the potential treatment of overactive bladder. R1481 presents two challenges for drug development. The first is the viscous semi-solid nature of the active pharmaceutical ingredient (API). The second challenge is the poor oral bioavailability of this water soluble, metabolically stable compound due to low intestinal permeability, and the P-glycoprotein (P-gp) efflux mechanism. Vitamin E TPGS is reported by others to enhance bioavailability by increasing the solubility of active compounds and by inhibiting P-gp in the intestine. In this report, compatibility of R1481 in Capmul MCM-based formulations with and without vitamin E TPGS is summarized. Review of accelerated stability studies of oral formulations led to the identification of a soft gelatin capsule formulation using neat Capmul MCM as an acceptable formulation for Phase 1 clinical studies. Soft gelatin capsules (5 mg strength) were manufactured with and without the addition of vitamin E TPGS. Clinical data show that vitamin E TPGS does not improve systemic exposure of R1481 in humans.
    MeSH term(s) Adult ; Animals ; Biopharmaceutics ; Capsules ; Chemical Phenomena ; Chemistry, Pharmaceutical ; Chemistry, Physical ; Cross-Over Studies ; Drug Evaluation, Preclinical/methods ; Female ; Gelatin/administration & dosage ; Gelatin/blood ; Gelatin/chemistry ; Humans ; Male ; Middle Aged ; Muscarinic Antagonists/administration & dosage ; Muscarinic Antagonists/blood ; Muscarinic Antagonists/chemistry ; Pharmaceutical Solutions/administration & dosage ; Pharmaceutical Solutions/chemistry ; Pharmaceutical Solutions/pharmacokinetics ; Swine ; Swine, Miniature ; Vitamin E/administration & dosage ; Vitamin E/blood ; Vitamin E/chemistry
    Chemical Substances Capsules ; Muscarinic Antagonists ; Pharmaceutical Solutions ; Vitamin E (1406-18-4) ; Gelatin (9000-70-8)
    Language English
    Publishing date 2004-09
    Publishing country United States
    Document type Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 3151-3
    ISSN 1520-6017 ; 0022-3549
    ISSN (online) 1520-6017
    ISSN 0022-3549
    DOI 10.1002/jps.20127
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top